HIV Infection Clinical Trial
Official title:
Effects of Mother Support Groups on Prevention of Mother-To-Child Transmission (PMTCT) Outcomes in Mutare & Makoni Districts, Zimbabwe: A Cluster Randomized Controlled Trial
The investigators hypothesize that a strategy of establishing facility-based mother support groups (MSGs) for HIV-positive mothers will result in increased retention rates of HIV-exposed infants in clinic-based PMTCT follow-up systems twelve months post-delivery compared to clinics that lack MSGs. The study will be conducted in health facilities in rural Mutare and Makoni health districts in Manicaland province, Zimbabwe. A two-arm cluster controlled study design will be used in 30 rural clinics randomly assigned to either arm to compare the effectiveness of MSGs. Arm 1 of the study consists of standard of care whilst arm 2 consists of standard of care together with facility-based MSGs.
PRIMARY OBJECTIVE To test whether MSGs lead to increased retention of HIV-exposed infants in
PMTCT programmes
SECONDARY OBJECTIVES
1. To assess whether MSGs lead to increased retention of mothers in postnatal HIV
follow-up care
2. To assess whether male participation in PMTCT activities is increased at clinics with
MSGs
3. To assess whether selected maternal and infant health indicators are improved in
HIV-positive mothers and their exposed infants at facilities with MSGs, viz. (1)
Antenatal attendance; (2) Delivery in facilities; (3) Infant immunisation uptake; (4)
Infant feeding methods and nutrition status; (5) Infant nevirapine prophylaxis; (6)
Infant co-trimoxazole prophylaxis; (7) Infant HIV testing; and (8) Family planning
uptake
MOTHER SUPPORT GROUP INTERVENTION MSGs were designed following formative research. A
non-governmental organisation established MSGs by recruiting HIV+ mothers and volunteer
coordinators (MSGCs) prior to commencing enrolment. MSGCs were HIV-positive mothers who were
trained in MSG establishment and maintenance, retention activities and data collection. MSGs
meet each two weeks with the MSGC or health worker facilitating an information session using
a curriculum of eight PMTCT-related topics. MSGCs send standard message reminders to
members, contact non-attending members by phone and inform health workers (HWs) to assist
retention. HWs conduct retention actions of non-attending patients in PMTCT programmes.
SAMPLE SIZE AND RANDOMISATION We excluded from the study low-volume facilities that recorded
booking fewer than 10 HIV-positive antenatal mothers per annum. We randomly selected
facilities in the two study districts to either of the study arms. Based on estimated infant
retention rates for control and intervention arms, we calculated the minimum sample size of
10 HIV-positive mothers to be enrolled at each health facility.
DATA COLLECTION, ANALYSIS AND QUALITY ASSURANCE The study utilizes the existing health
information system (e.g. antenatal care (ANC) Register, Exposed Infant Follow-Up Register,
Anti-retroviral treatment (ART) Register), supplemented by EPAZ study-related data
collection and patient tracking systems. Study staff will work with clinic- and
district-level staff to improve and collect routine and study-specific data. Data will be
entered, coded, cleaned and locked before analyses are made. Data will be analysed on an
intention-to-treat basis. A mobile team of well-trained quality assurance and control study
staff will be deployed throughout the data collection period to ensure quality of the
intervention and of data generated and collected at each study site. A pre-specified
proportion of patient visit records will be reviewed from each site.
;
Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care
Status | Clinical Trial | Phase | |
---|---|---|---|
Active, not recruiting |
NCT02135419 -
Treatment in Preventing Anal Cancer in Patients With HIV and Anal High-Grade Lesions
|
Phase 3 | |
Active, not recruiting |
NCT02663856 -
My Smart Age With HIV: Smartphone Self-assessment of Frailty
|
||
Terminated |
NCT02743598 -
Liraglutide for HIV-associated Neurocognitive Disorder
|
Phase 4 | |
Completed |
NCT02659306 -
Metformin Immunotherapy in HIV Infection
|
Phase 1 | |
Completed |
NCT02846402 -
Impact of HIV Self-testing Among Female Sex Workers in Kampala, Uganda
|
N/A | |
Completed |
NCT02663869 -
Aging With HIV at Younger vs Older Age: a Diverse Population With Distinct Comorbidity Profiles
|
||
Completed |
NCT02921516 -
Growing Up: Intervening With HIV-Positive Adolescents in Resource-Poor Settings
|
N/A | |
Completed |
NCT02564341 -
Targeting Effective Analgesia in Clinics for HIV - Intervention
|
N/A | |
Active, not recruiting |
NCT02302950 -
A Retrospective Analysis of Raltegravir Use in Minority HIV Infected Women in Houston, Texas
|
N/A | |
Completed |
NCT01830595 -
Lactoferrin Treatment in HIV Patients
|
Phase 2 | |
Completed |
NCT02269605 -
Bryostatin-1 Effect on HIV-1 Latency and Reservoir in HIV-1 Infected Patients Receiving Antiretroviral Treatment
|
Phase 1 | |
Terminated |
NCT01902186 -
Bone Mineral Density Changes in HIV-positive Females With Osteopenia Switching to Raltegravir
|
Phase 4 | |
Completed |
NCT01852942 -
Reversing Tissue Fibrosis to Improve Immune Reconstitution in HIV
|
Phase 2 | |
Terminated |
NCT02109224 -
Ibrutinib in Treating Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma in Patients With HIV Infection
|
Phase 1 | |
Completed |
NCT01946217 -
Factors Affecting Patient Participation in AIDS Malignancy Clinical Trials Consortium Clinical Trials
|
N/A | |
Completed |
NCT02118168 -
Observational Study for the Extended Follow-up of the Patients Enrolled in the Therapeutic Clinical Trial ISS T-002
|
N/A | |
Completed |
NCT02527135 -
Text Messaging to Improve HIV Testing Among Young Women in Kenya
|
N/A | |
Completed |
NCT02525146 -
Birmingham Access to Care Study
|
N/A | |
Active, not recruiting |
NCT02602418 -
Neural Correlates of Working Memory Training for HIV Patients
|
N/A | |
Completed |
NCT01680094 -
Safety and Effect of The HDAC Inhibitor Panobinostat on HIV-1 Expression in Patients on Suppressive HAART
|
Phase 1/Phase 2 |